Ralph DeFronzo, MD

Ralph DeFronzo, MD
 

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas


What attributes--mechanistically, metabolically, and physiologically--of GLP-1 RAs, in your mind, support their position as foundational agents across a broad spectrum of patients with T2D?

What attributes—mechanistically, metabolically, and physiologically—of GLP-1 RAs, in your mind, support their position as foundational agents across a broad spectrum of patients with T2D?

Within GLP-1 RAs, are there comparative distinctions--dosing, PK/PD, side effects, weight loss, lipid profiles, and BP--that have clinical relevance that should be highlighted? How do they differentially affect PPG?

Within the class of GLP-1 RAs, are there important comparative distinctions—dosing, PK/PD, side effects, weight loss, lipid profiles, and BP—that have clinical relevance that you believe should be highlighted? How do they differentially affect PPG?

What is the rationale of combining GLP-1 RAs and long-acting insulin into fixed ratio combination agents?

What is the rationale of combining GLP-1 RAs and long-acting insulin into fixed ratio combination agents?